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ABSTRACT
Purpose A versatile methodology is demonstrated for improving
dissolution kinetics, gastrointestinal (GI) absorption, and bioavail-
ability of protein kinase inhibitors (PKIs).
Methods The approach is based on nanoparticle precipitation by
sub- or supercritical CO2 together with a matrix-forming polymer,
incorporating surfactants either during or after nanoparticle for-
mation. Notably, striking synergistic effects between hybrid PKI/
polymer nanoparticles and surfactant added after particle forma-
tion is investigated.
Results The hybrid nanoparticles, consisting of amorphous PKI
embedded in a polymer matrix (also after 12 months), display
dramatically increased release rate of nilotinib in both simulated
gastric fluid and simulated intestinal fluid, particularly when surfac-
tants are present on the hybrid nanoparticle surface. Similar results
indicated flexibility of the approach regarding polymer identity,
drug load, and choice of surfactant. The translation of the in-
creased dissolution rate found in vitro into improved GI absorp-
tion and bioavalilability in vivo was demonstrated for male beagle
dogs, where a 730% increase in the AUC0–24h was observed
compared to the benchmark formulation. Finally, the generality of
the formulation approach taken was demonstrated for a range of
PKIs.
Conclusions Hybrid nanoparticles combined with surfactant
represent a promising approach for improving PKI dissolution
rate, providing increased GI absorption and bioavailability follow-
ing oral administration.
KEY WORDS bioavailability . carbon dioxide . hybrid .
nanoparticle . protein kinase inhibitor
INTRODUCTION
Dysregulation of protein kinases by mutation, gene
rearrangement, amplification, and overexpression has been
implicated in the development and progression of human
cancers (1). Protein kinases are frequently grouped according
to the amino acid, which phosphorylation they inhibit. Most
kinases act on both serine and threonine, while tyrosine ki-
nases act on tyrosine, and a number (dual-specificity kinases)
on all three. There are also protein kinases, which phosphor-
ylate other amino acids, including histidine. For indications
caused by the overexpression or up-regulation of protein
kinases, protein kinase inhibitors (PKIs) have attracted con-
siderable interest as therapeutics. For example, tyrosine kinase
inhibitors have been shown to be effective anti-tumor and
anti-leukemic agents, even if the gastrointestinal absorption
is low and highly variable with present formulations (2). Thus,
PKIs are generally weak bases, which dissolve only slightly at
low pH (typically 100–1,000 mg/L), and are practically insol-
uble at neutral pH (typically 0.1–10 mg/L). As a result of this,
PKIs display poor bioavailability following oral administra-
tion. Consequently, enhancing the solubility and/or dissolu-
tion rate of PKIs is key for improving the bioavailability and
efficacy/safety ratio of this class of anticancer drugs.
Several methods for improving the dissolution characteris-
tics of poorly water-soluble drugs have been reported, includ-
ing micronization, as well as the formation of solvates, salts,
complexes, and nanoparticles. Nanoparticular formulations
provide opportunities of increased dissolution rate of sparingly
soluble drugs through decreased particle size (and correspond-
ingly higher Laplace pressure), and through destabilization of
the crystalline state. Drug-containing nanoparticles can be
generated through a range of approaches, including top-
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down methodologies such as media milling and homogeniza-
tion, as well as bottom-up approaches such as controlled
nucleation and nanoparticle growth in confinement. Due to
the high energy state of such nanoparticles, however,
maintaining their state of dispersion requires stabilization,
which can be achieved, e.g. , either by adsorbing a stabilizing
surfactant or polymer layer on the nanoparticle surface, or by
embedding the nanoparticles in a matrix, thus being equiva-
lent to solid dispersions in the microscale (3–5).
Hybrid nano- and microparticles may be prepared by
various techniques, including spray-drying, spray-cooling,
spray freeze-drying and electrospraying, all having their
strengths and weaknesses. Alternatively, nanoparticle forma-
tion can be achieved by approaches involving sub- and super-
critical CO2, which offer opportunities related to, e.g. , efficient
solvent removal, fast processing, and process scalability. In the
particular case of PKIs, CO2 precipitation is a powerful
technique since it can be combined with poorly volatile sol-
vents, notably DMSO, which are among very few solvent able
dissolve sufficient PKI concentrations to generate high drug
loads in the resulting nanoparticles.
Some of these approaches are based on CO2 as a solvent,
generating particles on expanding the system, while others are
based on CO2 as an anti-solvent, in combination with one or
several organic solvents (6–14). The former offer the best
option in the idealized case, since supersaturation of the order
of 105–106 can be achieved at a time scale of 10−6–10−4 s,
facilitating solvent-free generation of very small particles of a
high degree of homogeneity. Due to the poor solvency
displayed by most pharmaceutically interesting excipients (no-
tably polymers and surfactants) in CO2, however, substantially
larger flexibility is obtained when CO2 is used as an anti-
solvent rather than as a solvent (14–16). Examples of polymers
used in the latter context include, e.g. , polyvinyl alcohol,
hydroxypropyl methylcellulose (HPMC), ethyl cellulose/
methyl cellulose, and polyesters, while solvents used include,
e.g. , DMSO, DMF, methylene chloride, and ethyl acetate
(14,16,17).
Even for such a seemingly simple system and process,
however, the materials generated depend on a range of com-
position and processing conditions. For example, faster flow of
CO2 has been reported to be favourable for reducing particle
size as well as the residual solvent level in the case of DMSO
(12). Furthermore, a range of composition parameters have
been found to play a key role in determining the structure and
function of polymer-based (nano)particles, including polymer
crystallinity (18), glass transition temperature (19), and surface
activity (20,21). Also, the drug load in such hybrid
nanoparticles critically affects their physical state, notably the
crystallinity and crystal habit.
Given the need for improved gastrointestinal (GI) absorp-
tion and bioavailability of PKIs, as well as the opportunities
offered by sub- and supercritical CO2 as anti-solvent, we here
report a versatile formulation strategy based on hybrid
nanoparticles formed by PKIs in the presence of matrix-
forming polymers and swelling/solubilizing surfactants. In
doing so, we investigate effects of polymer concentration and
drug load, as well as of surfactant presence and processing
conditions. Notably, the manuscript reports on striking syner-
gistic effects between hybrid PKI/polymer nanoparticles and
surfactant added after particle formation. For selected formu-
lations, detailed physicochemical characterization is provided
through X-ray diffraction, modulated differential scanning
calorimetry, vapor sorption measurements, and electron mi-
croscopy, and increased bioavailability demonstrated as proof
of concept in male beagle dogs. Finally, generalization of the
approach to other PKIs is demonstrated.
MATERIALS AND METHODS
Chemicals
Hydroxypropyl methylcellulose phtalate (HPMCP; HP55)
was from Shin-Etsu (Tokyo, Japan), while polyvinyl acetate
phthalate (PVAP; 2138 Clear) was from Colorcon
(Harleysville, USA), polyvinylpyrollidone (PVP; K90) from
Sigma-Aldrich (St. Louis, USA), 2-hydroxypropyl-β-cyclodex-
trin from Alfa Aesar (Karlsruhe, Germany), methacrylic acid-
methyl methacrylate copolymer (1:1) (Eudragit L100) from
Evonik Industries (Darmstadt, Germany), poly(ethylene ox-
ide)-poly(propylene oxide)-poly(ethylene oxide) block copoly-
mer (Lutrol F127) from BASF (Ludwigshafen, Germany),
hydroxypropyl methylcellulose USP2910 (Pharmacoat 645)
from Shin-Etsu Chemical Co. (Tokyo, Japan), hydroxypropyl
methylcellulose USP2910 (Methocel E15) from Dow Chem-
ical Company (Midland, USA), and hydroxypropyl methyl-
cellulose acetate succinate (HPMC AS) from Shin-Etsu
Chemical Co. (Tokyo, Japan). Polyvinylcaprolactone-
polyvinylacetate-polyethylene glycol (Soluplus) and D-α-
tocopherol polyethylene glycol 1000 succinate (TPGS) was
from BASF (Ludwigshafen, Germany) and Sigma (St. Louis,
USA), respectively. While Soluplus is strictly a block copoly-
mer, it will here be referred to as “surfactant” for simplicity.
Nilotinib base and HCl salt was from Hwasun Biotechnology
Co. (Shanghai, China), while lapatinib, pazopanib, erlotinib,
gefitinib, sorafenib, dasatinib, and sunitinib were all obtained
from Tecoland (New Irvine, USA). Nilotinib hydrochloride
monohydrate (Tasigna) was from Novartis (Basel, Switzer-
land) (lot 09 2014 S0028).
SCF Apparatus
Figure S1 shows a simplified representation of the supercriti-
cal fluid (SCF) processing system used for hybrid nanoparticle
generation. The system consists of one pumping set-up for the
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solution containing the active ingredient (PKI dissolved in a
solvent, together with excipients where applicable) and one for
the anti-solvent (CO2). The two set-ups are connected at a
nozzle (located in the reactor) where particles are produced by
anti-solvent precipitation. Particles are retained in the reactor
by a filtering set-up. A back-pressure regulator is used after the
reactor for pressure control. Each pumping set-up is equipped
with separate flow and pressure meters for good process
control. Before nanoparticle generation, CO2 and solvent are
pumped through the system (at 100 g/min and 1 mL/min,
respectively) until flow rates, pressure (125 bar), and tempera-
ture (15°C) have reached steady state. The solvent is then
replaced by solvent containing the PKI (as well as excipients
where applicable), and nanoparticles produced in the reactor.
After completion of pumping of the PKI-containing solution,
CO2 is pumped through the reactor in order to extract residual
solvent from the reactor and the powder. Finally, the reactor is
depressurized, and the sample collected.
Scanning Electron Microscopy (SEM)
Environmental SEM experiments were performed using a
FEI-Philips-XL 30 TMP-PW 6635/45 microscope (Eindho-
ven, Netherlands), operating at 20–22 kV. For sample prep-
aration, a Balzers SCD 050 (Balzers, Liechtenstein) sputtering
equipment was employed to render the samples electrically
conductive, thereby preventing image distortion from electri-
cal charge build-up, and achieving better secondary electron
emission. In doing so, argon gas was introduced to the spec-
imen chamber. After repeated chamber flushing with argon, a
pressure of 0.05–0.1 mbar was established. High voltage
(giving 40 mA) was subsequently applied to create a field
between the target (cathode) and the specimen table (anode),
resulting in glow discharge and release of metal atoms from
the gold target. By this treatment, the specimen surface, even a
very fissured one, is coated with a homogeneous metal layer
(≈10 nm) of sufficient electrical conductivity for SEM
examination.
Laser Diffraction
Particle size distributions were obtained by laser diffraction,
using aMastersizer 2000 (Malvern,Worcestershire, UK). Due
to van der Waals interactions, as well as humidity-induced
swelling of the polymer matrix, agglomeration of primary
particles is likely. In order to reduce such primary particle
agglomeration, but also to limit dissolution in the dispersion
media, light diffraction measurements were performed, after
sonication, in Volasil 244 (VWR International, Lutterworth,
U.K.), using a refractive index of 1.394. The cuvette was
initially filled with Volasil only, after which nanoparticles were
added under stirring (500 rpm) until a suitable light scattering
intensity was obtained. For each sample, triplicate
measurements were performed at room temperature, and
particle size distributions calculated based on a refractive
index and an absorption of the nanoparticles of 1.50 and
0.001, respectively.
Z-Potential Measurements
Measurements of z-potential of hybrid nanoparticles were
performed by dynamic light scattering at a scattering angle
of 173°, using a Zetasizer Nano ZS (Malvern Instruments,
Malvern, UK). Measurements were performed in duplicate at
25°C. For nilotinib/HPMCP (40/60 wt/wt), z-potential was
determined (in 1 mM Tris, pH 7.4) to −29.4±0.4 and −28.5
±1.3 mV for surfactant added before and after nanoparticle
formation, respectively. While interpretation of z-potential
data for diffuse nanoparticles is precluded by hydrodynamic
(and swelling-dependent) interactions, these results neverthe-
less show that, apart from steric stabilization due to the swell-
ing polymer matrix and the block copolymer surfactants,
electrostatics contribute to the colloidal stabilization of these
systems.
X-Ray Powder Diffraction (XRD)
XRD experiments were run on an X’Pert Pro diffractom-
eter (PANanalytical, Almelo, Netherlands) set in Bragg-
Brentano geometry. The diffractometer was equipped with
20 μm nickel filter and an X’Celerator RTMS detector
with an active length of 2.122° 2θ. A representative sam-
ple was placed on a zero background quartz single crystal
specimen support (Siltronix, Archamps, France). Experi-
ments were run using Cu Kα radiation (45 kV and
40 mA) at ambient temperature and humidity. Scans were
run in continuous mode in the range 4.5–40° (or 2–50°)
2θ using automatic divergence and anti-scatter slits with
observed length of 10 mm, a common counting time of
299.72 s, and step size of 0.0167° 2θ. Data collection was
done using the application software X’Pert Data Collector
V.2.2j and instrument control software V.2.1E, while pat-
tern analysis was done using X’Pert Data Viewer V.1.2c
(all software being from PANanalytical, Almelo,
Netherlands).
Dynamic Vapour Sorption (DVS)
The hygroscopicity of the samples was studied by Dynamic
Vapor Sorption Gravimetry (DVS), using a DVS-1 (Surface
Measurement Systems, Alperton, UK). Approximately 10 mg
of the substance was weighed into a glass cup. The relative
weight was recorded at 20 s interval when the target relative
humidity (RH) over the sample was increased stepwise from
0% to 90%, and then similarly decreased back to 0% RH,
with 10% RH per step. Each sample was run in three
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consecutive full cycles. The condition to proceed to the next
level of RH was a weight change below or equal to 0.002%
within 15 min, with a maximum total time per step of 24 h.
Due to slow equilibration in experiments of this type, the
numbers obtained should be regarded as lower estimates of
water uptake. The temperature was kept at 25°C.
Modulated Differential Scanning Calorimetry (mDSC)
Modulated Differential Scanning Calorimetry (mDSC) anal-
ysis was run on a TA Instruments Model Q200 (New Castle,
USA), equipped with a RC90 refrigerated cooling system
(Home Automation, New Orleans, USA). Samples were
weighed to 7±2 mg in Tzero Low–mass aluminum pans
and sealed with Tzero lids. They were then heated at a rate
of 3˚C/min from 0 to 170°C with conventional modulation
temperature amplitude of 1°C and a modulation period of
40 s. Ultra-high purity nitrogen was used as purge gas at a flow
rate of 50 mL/min. All data analyses were performed using
TA Universal Analysis software, version 4.7A. Cell constant
and temperature calibrations were conducted with the use of
an indium standard prior to instrument operation. DSC re-
sults were evaluated in terms of both forward and reversing
components of heat flow. As all notable thermal events were
captured and more clearly illustrated by the reverse compo-
nent of heat flow, the DSC results are presented as reversing
heat flow.
Determination of Surfactant Concentration
Surfactant/block copolymer content was determined by
HPLC-RI, using an Alliance 2695 equipped with a 2410
differential refractometer (Waters, Milford, USA). Chromato-
graphic conditions used included an injection volume of 20 μl,
and a mobile phase of dimethylformamide (DMF; Thermo
Fisher Scientific, Waltham, USA) at 0.9 mL/min. The col-
umn used was a Pathfinder AS Silica 100 3.5 μm RP 4.6×
150 mm (Shimadzu Scientific Instruments, Columbia, USA),
and chromatograms were evaluated using software fromClar-
ity International (North Sydney, Australia). The amount of
Soluplus in hybrid nanoparticles was determined by adding
0.100 mL sample solution (1.07 mg/mL in DMF) to six
separate HPLC vials. To four vials, different amount (0.050,
0.100, 0.200, and 0.300 mL) of Soluplus standard solution
(1.02 mg/mL in DMF) was added. DMF was then added to
each vial to give a total volume of 1.00 mL. The samples were
run on above HPLC system. A standard curve was then
constructed and the amount of Soluplus determined.
Determination of Residual Solvent
The amount of residual DMSO was determined by GC-MS,
using a Varian 3800GC, equipped with a Varian 1200 Single
quadropole mass spectrometer (Varian, Paolo Alto, USA). A
Zebron ZB 624 fused silica column (60 m×0.25 mm id, df=
0.14 μm) (Phenomenex, Torrance, USA) was used, initially
keeping the oven temperature at 70°C for 3 min, followed by
a temperature increase to 130°C at 3°C/min, then at 6°C/
min to 200°C, and finally to 250°C at 50°C/min, followed by
a final hold. Helium was used as a carrier gas at 1.2 mM/min,
and samples were injected at 1 μL at 275°C in a split flow
(100 mL/min) configuration. MS conditions included EI ion-
ization, a scan range of 20–600 m/z, a filament current of
150 μA, an ion source temperature of 200°C, and a manifold
temperature of 40°C. After construction of a standard curve,
sample concentrations were determined.
Dissolution (Batch)
3.5 mg of nilotinib base equivalent was added to an 8mL glass
bottle, whereafter 7 mL of solution (fasted state simulated
intestinal fluid (FaSSIF)) (22) was added. Bottles were then
placed on a shaker (40 rpm) for dissolution. Samples of 500 μl
where taken after different times, and subsequently centri-
fuged at approximately 13,000 g for 3 min. The resulting
supernatant was then analyzed by HPLC (C18 column
Eclipse, 4.6 mm×15 cm, Agilent Technologies, Santa Clara,
USA), with a mobile phase (1 mL/min) consisting of
methanol/acetonitrile/water/trifluoro acetic acid (23/23/
44/0.1 (v/v)) (VWR/Prolabo, Leuven, Belgium), and detec-
tion at 254 nm.
Dissolution (USP4)
Dissolution according to USP4 was performed by off line
HPLC. The system used consisted of a Dissotest CE1
equipped with a cell for testing powder (Sotax, Allschwil,
Switzerland), a Scantec 650 HPLC pump (Partille, Sweden),
and an RM 20 LAUDA water bath (Artisan Technology
Group, Champaign, USA). For dissolution in FaSSIF and
SGF (Biorelevant, Croydon, U.K.) (22), an Agilent 1100
HPLC system was used, equipped with a degassing unit, a
binary pump, a thermostated auto sampler, a column heater,
and diode array detector, all from Agilent (Palo Alto, USA).
An injection volume of 5 μL was used, together with a mobile
phase (1.0 mL/min) of methanol/acetonitrile/water/trifluoro
acetic acid (23/23/44/0.1 (v/v)). The column used was a
Zorbax Eclipse XDB-C18 5 μm 4,6 mm*150 mm (Agilent
Technologies, Santa Clara, USA), and data was evaluated by
Chemstation (Agilent, Palo Alto, USA). A sample containing
3.5 mg PKI was placed in the dissolution cell. The cell was
then placed in 37°C water bath. The pump was operated at
8 mL/min. Samples (approx 0.9 mL) were collected at pre-
determined intervals, analyzed offline, and the amount deter-
mined through external calibration.
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Animal Experiments
Pharmacokinetic studies in beagle dogs were conducted under
Animal Care and Use Committee (IACUC) protocols 11IA6
and 12IA13. Samples (5 mg/kg) for in vivo experiments were
pre-filled size 0 hard gelatin capsules (Capsugel, Colmar,
France) and stored in a desiccator at room temperature,
protected from light, until use. Animal experiments were
designed to focus on the performance of the best hybrid
nanoparticle formulation in comparison with two control
formulations, restricting studies of variations in drug load,
polymer/surfactant concentration and type, as well as pro-
cessing conditions, to in vitro investigations. As controls, a
0.2 mg/mL formulation consisting of 10% hydroxypropyl-ß-
cyclodextrin in water (with pH and osmolarity adjustment)
was used, as was a commercial benchmark formulation
(Tasigna). The systemic exposure following oral administra-
tion was evaluated (non-blinded) in male beagle dogs. Each
formulation was dosed in quadruplicate in each group for a
total of 24 dogs (crossover). Animals were supplied with a
commercial diet and water ad libitum prior to study initiation.
Food was then withheld from the animals for a minimum of
twelve hours before the study, as well as during the study until
four hours post dose, when food was returned. For the
hydroxypropyl-ß-cyclodextrin formulation of nilotinib, ani-
mals received test compound by intravenous infusion for
30 min. All other animals received a dose by capsule at time
zero on the day of dosing. Five minutes prior to dosing, the pH
of the stomach was neutralized using oral administration of
10 mL of a sodium bicarbonate solution in water (100 mg/
dog, 10 mg/mL, 10 mL/dog). After dosing of the capsules,
50 mL of water was administered as a flush. Blood samples
were collected via the jugular vein and placed into chilled glass
microtainer tubes containing sodium heparin. Samples were
centrifuged (4°C) at 3,000 g for 5 min. Plasma samples were
then transferred into labeled polypropylene tubes, placed on
dry ice, and stored in a freezer set to maintain −60°C to
−80°C. Nilotinib concentration was determined by LC-MS/
MS using a single eight-point standard curve and quality
control samples at three levels with six replicates each. Phar-
macokinetic parameters were calculated from the time course
of the plasma concentration. The maximum plasma concen-
tration (Cmax) and time to the maximum plasma drug con-
centration (tmax) were calculated using the non-
compartmental model, while the area under the plasma drug
concentration-time curve from 0 to 24 h (AUC0–24h) was
calculated using the trapezoidal formula. The Mean Resi-
dence Time (MRTlast) was calculated from AUMC/AUC
(AUMC being the area under the first moment curve) to the
last observable time point (24 h), and the plasma half-life (t1/2)
from 0.693/slope of the terminal elimination phase. Data are
reported as mean ± standard deviation of means (SD). A
minimum of four animals per time point was used. All
statistical tests were performed using Graphpad Prism (Ver-
sion 4.00; Graphpad Software Inc., SanDiego, CA). Student’s
t-test was performed at 95% confidence intervals, and a
minimum p value of 0.05 was used as the significance level.
RESULTS
Due to unique physicochemical properties, sub- and super-
critical CO2 displays poor miscibility with a wide range of
pharmaceutical excipients. While this limits the use of CO2 in
nanoparticle formation based on expansion methodologies,
this is a major advantage in nanoparticle formation through
the use of CO2 as anti-solvent. Thus, efficient particle forma-
tion and solvent removal can be achieved also with solvents of
high boiling point, e.g. , DMSO, which are often last resort
solvents for sparingly soluble drugs. Demonstrating the im-
portance of the latter, Table S1 shows solubility estimates of a
range of PKIs in a range of commonly used solvents. As can be
seen, the PKIs investigated are characterized by limited to
poor solubility in all solvents except DMSO. While DMSO is
frequently used as solvent for a range of sparingly soluble
drugs, it is also notoriously difficult to remove. With nanopar-
ticle generation using CO2 as anti-solvent, however, even
DMSO is efficiently removed. For example, residual DMSO
in hybrid nanoparticles formed by nilotinib/ HPMCP (40/60
wt/wt) was found to be below 50 ppm (results not shown).
Such low levels of residual solvent are attractive from a safety
perspective, but also from marginal solvent plastization,
resulting in limited material re-organization after particle
formation, and hence in an increased physical stability.
As demonstrated in Fig. 1, CO2-generated nilotinib parti-
cles are highly crystalline, with similar structural characteris-
tics as unprocessed nilotinib, but with considerable smaller
particle size. On co-precipitation in the presence of a polymer,
drug incorporation in a polymer matrix is anticipated. Dem-
onstrating this for nilotinib/ HPMCP particles (Fig. 2a, b),
Fig. 2c shows XRD pattern at a (nilotinib/polymer) drug load
of 40 wt%. As can be seen, nilotinib is amorphous in the
composite particles generated, and remains so even after at
least 12 months of storage at 20°C (ongoing for multiple
batches; for pazopanib and lapatinib the corresponding num-
ber is 12 and 14months, respectively (ongoing)). Efficient drug
encapsulation is obtained up to a drug-load of ≈60 wt%, as
inferred from XRD data on amorphicity/crystalinity (Fig. 2c)
and from the drug-load-dependent dissolution rate (Fig. 3b).
In line with this, modulated differential scanning calorimetry
(Fig. 2d) displays a high single glass transition temperature at
127°C, reporting on an amorphous phase of good stability.
Quantitatively, the Tg obtained for nilotinib/ HPMCP (40/
60) is similar to that of HPMCP in the absence of nilotinib.
Further indicating that the continuous phase in the hybrid
nanoparticles is indeed formed by the polymer, dynamic
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vapor sorption (Fig. 2e) shows a fair amount of water uptake
with increasing relative humidity, but again no sign of
humidity-induced phase transitions. (XRD analysis confirmed
that the hybrid nanoparticles remained amorphous after these
experiments (results not shown).) This is in stark contrast to
nilotinib raw material, which displays much less water uptake.
Together, the small variation in Tg, also at high drug load, the
nanoparticle amorphicity, and a water uptake higher than
that expected from the weighted average between the
HPMCP and nilotinib components, suggest that nilotinib is
present as small disordered domains within the hybrid
nanoparticles, rather than being molecularly distributed
(23,24).
In order to get further indication on the performance of the
hybrid nanoparticles, in vitro dissolution kinetics of nilotinib
was monitored. As can be seen in Fig. 3a, nilotinib/ HPMCP
nanoparticles display much higher dissolution rate than both
nilotinib raw material and the physical mixture of nilotinib
and HPMCP. These results are therefore compatible with the
physicochemical characterization discussed above. It should
here be noted that HPMCP is not the only matrix-forming
polymer able to achieve dramatic improvement in nilotinib
dissolution kinetics. Instead, similar results were obtained with
PVAP and a number of other matrix-forming polymers
(Figure S2). The formulation approach also allows flexibility
in polymer concentration/drug load, in favourable cases
allowing drug loads up to 60% (Fig. 3b).
To further improve the dissolution kinetics from the hybrid
nanoparticles, surfactant/block copolymer was added to the
polymer/PKI formulation. Such surfactants/block copoly-
mers not only solubilize the PKI through micelles formed
(25,26), but also cause swelling of the polymer matrix in
aqueous solution, and promote dissolution of the outer layer
once the latter is sufficiently swollen with water, thereby
resulting in a reduced diffusion barrier and faster dissolution
kinetics. As demonstrated in Figs. 4 and S3, respectively,
Soluplus and TPGS both result in pronounced enhancement
of the dissolution rate of nilotinib, compared to results
obtained in the absence of surfactant. An important aspect
of the presence of surfactant as dissolution enhancer in these
systems, however, is that of how surfactant is introduced to the
hybrid nanoparticle formulation. Thus, as shown in Figs. 4
and S3, surfactant dissolved in the organic solvent together
with polymer and PKI prior to CO2-induced precipitation
resulted in substantially smaller dissolution enhancement than
surfactant added after PKI/polymer hybrid nanoparticle for-
mation. Since chemical analysis showed that surfactant was








































Fig. 1 Effect of CO2 processing on
crystallinity and morphology of
nilotinib. Shown in (a ) and (b ) are
XRD and SEM data for
unprocessed (left) and CO2-
precipitated (right) nilotinib.
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22 wt% in 25/38/36 nilotinib/ HPMCP /Soluplus), the
origin of this effect is not only due to “material loss” at
processing equipment surfaces or the like. Instead, the com-
bined results indicate that surfactant added prior to particle
formation is embedded in the hybrid nanoparticles, thus only
partly accessible for maximum swelling and solubilization. In
contrast, surfactant added after PKI/polymer particle forma-
tion is localized at the particle surface, thereby being optimally
placed for promotion of both matrix swelling/dissolution and
PKI solubilization. It is important to note, however, that the
surfactant alone is not responsible for this effect, as the
corresponding physical mixture between PKI, polymer, and
surfactant does not result in high dissolution rate. Thus, de-
spite having the same surfactant content, the physical mix of
nilotinib, HPMCP (or PVAP), and Soluplus (or TPGS) dis-
plays <10% dissolution compared to the hybrid nanoparticles
(Figs. 4a and S3). Clearly, therefore, it is the combined effect of
the matrix (resulting in small amorphous embedded PKI
nanodomains in the polymer matrix) and the surfactant (caus-
ing matrix swelling/dissolution and enabling PKI solubiliza-
tion in released micelles), which result in the strong enhance-
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HPMCP hybrid nanoparticles (40/
60 wt/wt). Shown are results
obtained by (a ) laser diffraction, (b )
SEM, (c ) XRD, (d ) modulated
DSC, and (e ) dynamic vapour
sorption (RH: 0->90%->0%). In
(d), water content was 2.1±
0.1 wt% and 1.7±0.1 wt% in the
HPMC and the nilotinib/ HPMCP
(40/60 wt/wt) sample, respectively.
In (c), retained amorphicity is
demonstrated after 0 month and
after 12 months of storage at 20°C.
Shown also in (c ) is XRD data on
(crystalline) nilotinib/ HPMCP at a
70 wt% drug load. (XRD
measurements after 12 months
were obtained also at longer
exposure times; Figure S4,
Supporting Material.)
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As discussed above, the approach taken allows quite some
flexibility in both polymer concentration and drug load, as
well as in the nature of the polymer and that of the surfactant.
As illustrated in Fig. 5, this flexibility holds also with regard to
the drug itself, as a strong increase in dissolution kinetics is
obtained for a range of PKIs. The relative enhancement in
PKI dissolution kinetics, i.e. , nilotinib ≈ lapatinib > pazopanib
≈ erlotinib > gefitinib ≈ sorafenib > dasatinib > sunitinib, is a
reflection of both the properties of the nanoparticles and those
of the PKI rawmaterial. Although there is thus a spread in the
extent of dissolution improvement reached with the different
PKIs (the detailed analysis of which goes beyond the scope of
the present investigation), the flexibility offered by the present
formulation approach is clear.
In order to further investigate the relevance of the in-











































Fig. 3 (a ) Role of polymer matrix for (USP4) dissolution kinetics of nilotinib in
FaSSIF. Shown are dissolution curves for nilotinib/ HPMCP hybrid
nanoparticles, as well as data for the corresponding physical mixture between
nilotinib and HPMCP, both at a nilotinib/polymer ratio of 40/60 wt/wt, as well
as data for nilotinib raw material. (b ) Effect of polymer fraction of nilotinib/
polymer nanoparticles on dissolution rate in FaSSIF, expressed as “Relative
Solubility”, the ratio of the amount nilotinib dissolved from the hybrid
nanoparticles after 90 min compared to that of raw nilotinib at a constant















































Fig. 4 Role of surfactant (Soluplus) on nilotinib (batch) dissolution kinetics in
FaSSIF. The results are expressed as “Relative Solubility”, the ratio of the
amount nilotinib dissolved from the hybrid nanoparticles after 90 min com-
pared to that of raw nilotinib at a constant drug load of 40 wt%. Results are
shown for surfactant added after nilotinib/polymer nanoparticle formation
(“surface distribution”), for surfactant present together with polymer and
nilotinib during nanoparticle formation (“matrix distribution”), and for the
physical mix of raw nilotinib, polymer, and surfactant (“physical mix”) (a ). In
(b ), the effect of amount of surfactant added (“surface distribution”) on the
dissolution of nilotinib/ HPMCP (40/60 wt/wt) hybrid nanoparticles is shown
as well.
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absorption and bioavailability following oral administration,
the release of nilotinib was investigated for a selected formu-
lation in simulated gastric fluid (SGF) and fasted state simu-
lated intestinal fluid (FaSSIF). Generally being bases, PKIs
display some solubility at low pH (e.g. , in the stomach), but
dramatically reduced solubility with increasing pH. There is
therefore a risk of re-precipitation of the PKI in the intestine,
and it is thus of interest to investigate PKI dissolution rate
under conditions simulating these latter conditions. As can be
seen in Fig. 6, nilotinib indeed displays the expected higher
dissolution rate in SGF due to its protonation at the low pH of
SGF (pH≈1.6) (22). Importantly, however, dissolution rate
remains good also in FaSSIF (pH≈6.5), in stark contrast to
benchmark nilotinib formulation (Tasigna), which display
very poor dissolution at the latter conditions.
After thus having demonstrated that nilotinib displays im-
proved in vitro dissolution rate from the hybrid nanoparticle
formulation in biorelevant media, compared to the clinically
used benchmark formulation, the next step was to investigate
whether the promising release results obtained in vitro translate
also to in vivo GI absorption and bioavailability following oral
administration. As shown in Fig. 7, the hybrid nanoparticle
formulation of nilotinib increased GI absorption and bioavail-
ability in male beagle dogs after oral administration of cap-
sules containing the hybrid nanoparticles. Quantitatively,
AUC0-24h for nilotinib/ HPMCP/Soluplus nanoparticles
(26/34/45 wt/wt) was 730% of that of the benchmark
nilotinib formulation (Tasigna). Furthermore, while the two
formulations displayed comparable tmax and MRTlast, the
nanoparticle formulation displayed signtificantly higher t½
(Table S2). In conclusion, therefore, the presently investigated
approach is clearly of relevance also for enhancing bioavail-
ability of PKIs following oral administration.
DISCUSSION
When forming polymer-drug particles by precipitation, parti-
cle structure and morphology depend on a number of param-
eters. While a more or less complete amorphization is most





































Fig. 5 Generalization of the formulation concept. Shown are dissolution data
under sink conditions (USP4) for erlotinib/ HPMCP (35/65 wt/wt), compared
to unprocessed erlotinib (a ), as well as (b ) the relative enhancement (com-
pared to the unprocessed material) after 90 min in FaSSIF for a range of PKIs
(1 : sunitinib maleate; 2 : dasatinib; 3 : gefitinib; 4 : sorafenib tosylate; 5 :





















Fig. 6 Dissolution under sink conditions (USP4) of nilotinib/ HPMCP (40/60
wt/wt) in SGF and FaSSIF, compared to benchmark nilotinib (Tasigna).
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investigated systems (except at very high drug loads), also
transitions from one ordered polymorph to another may be
observed. As an example of the latter, Matsuda et al. observed
a polymorphic transformation in phenylbuthasone, from the
stable δ form to a metastable β form (28). In the case of
amorphization through nanoparticle formation, by use of
CO2 or otherwise, it is frequently of interest to maintain this
amorphous state, at least as long as a stable crystal form
cannot be obtained at maintained particle size. In line with
the excellent storage stability observed in the present investi-
gation, Lim et al. , previously demonstrated that co-
precipitation of indomethacin with poly(vinylpyrrolidone)
(PVP) provides stability against crystallization, the protective
effect increasing with PVP molecular weight and concentra-
tion (27). Similarly, Kluge et al. , investigated co-formulations
between sparingly soluble phenytoin and PVP K30, using
CO2 as anti-solvent, and found that particle crystallinity
depended critically on the polymer/drug ratio (29). In line
with the present finding of fully amorphous hybrid
nanoparticles up to 50 wt%, but crystallinity at 70% nilotinib,
these authors found that phenytoin concentrations up to
40 wt% results in fully amorphous particles (≈200–500 nm),
in analogy to particle formation of the polymer in the absence
of drug. At higher drug concentrations, on the other hand,
crystalline drug particles were obtained (≈20–60 μm).
Essentially independent of production process, agglomera-
tion and incomplete re-dispersion of dry nanoparticle powders
frequently represents a formidable challenge. However, by
coating the particle surfaces with a surfactant and/or a poly-
mer, van derWaals and capillary interactions can be reduced,
agglomeration suppressed, and re-dispersion facilitated (30).
As suggested by the pronounced enhancement of PKI disso-
lution rate in the presence of surfactant, and more straight-
forwardly demonstrated by the light diffraction results, this is
the case also for the presently investigated systems. As dem-
onstrated, e.g. by Breitenbach et al. , a high degree of polymer
crystallinity may also reduce agglomeration due to reduced
swelling (18). This was further demonstrated by Bodmeier
et al. , who found polymers with a low glass transition temper-
ature to display pronounced agglomeration at room temper-
ature, while agglomeration was less pronounced for polymers
with a high glass transition temperature (19). These findings
are therefore comparable with the present results, as the high
glass transition demonstrated for the nilotinib/HPMCP/
Soluplus system correlates to limited agglomeration, high
nilotinib release rate, and good storage stability.
Addressing the issue of surface stabilization of drug
nanoparticles, although not prepared by CO2 precipitation,
Van Eerdenbrugh et al. investigated 13 different surfactant
and polymer stabilizers for 9 structurally different drugs (31).
Generally, homopolymers, both synthetic and those of natural
origin (e.g. , alginate and poly(vinyl alcohol) (PVA)) were un-
able to stabilize the nanoparticles, although PVP displayed
somewhat better performance. Also a number of cellulose
derivatives, e.g. , hydroxypropyl methylcellulose (HPMC),
methyl cellulose (MC), hydroxyethyl cellulose (HEC),
hydroxypropyl cellulose (HPC), and sodium carboxymethyl
cellulose (NaCMC), displayed relatively modest stabilization
of the drug nanoparticles, presumably due to a modest surface
accumulation of these polymers at the drug particles at the low
polymer concentrations used. In contrast, block copolymers
(Poloxamer 188 and PVA-poly(ethylene glycol) graft copoly-
mer) were more efficient in drug particle stabilizations, while
the most effective particle stabilization was achieved by Poly-
sorbate 80 and D,α-tocopherol-poly(ethylene glycol)-1000-











































Fig. 7 Average plasma concentration versus time (a ) and AUC0–24h (b ) of
nilotinib in male beagle dogs following oral administration of capsules contain-
ing either nilotinib/HPMCP/Soluplus (26/34/45 wt/wt) or benchmark nilotinib
(Tasigna) at a dose of 5 mg/kg. In (b ), comparison with results obtained for
nilotinib infused together with hydroxypropyl-β-cyclodextrin is included as
well.
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the drugs investigated. Furthermore, it was demonstrated that
particle stabilization was directly correlated to the density of
surfactant/polymer adsorbed to the particle surfaces. Also
other studies have addressed these issues, observing stabilizing
effects of, e.g. , cellulose ethers such as HPMC and EHEC
(32–34). Thus, nanoparticle stabilization through adsorption
requires highly surface active polymers and surfactants, while
stabilization through matrix formation places weaker require-
ments on this.
In a parallel study, Van Eerdenbrugh et al. investigated the
stabilization of nanoparticles generated from 9 different drugs
by TPGS.While the surfactant was able to provide protection
against agglomeration, it was unable to halt Ostwald ripening,
i.e. , the growth of larger particles on expense of smaller ones
through curvature-dependent solubility (35). Similarly, Lee
et al. investigated a number sparingly soluble drug particles
stabilized by either HPC, PVP, Pluronic F127, PEG, or
Pluronic F68, and found that drugs with a lower solubility
were more straightforwardly stabilized against particle growth
(through Ostwald ripening) than more extensively soluble
ones (36). Notably, surface active Pluronic (PEO-PPO-PEO)
block copolymers, and to some extent also PVP and HPC,
were able to stabilize particles formed by drugs of poor solu-
bility, whereas the less surface active PEG was considerably
less efficient.
As thus seen, numerous factors contribute to making poly-
mer encapsulation of amorphous drug nanoparticles a com-
plicated process. However, as long as the low drug solubility in
aqueous solution is not primarily due to high stability of the
solid state, and low enough to avoid Ostwald ripening (as with
PKIs), and a suitable polymer for matrix formation (preferably
with a high Tg) can be identified, hybrid nanoparticles are
efficient in enhancing dissolution rate and improving oral
bioavailability of sparingly soluble drugs. As demonstrated
for PKIs in the present investigation, presence of surfactant
is critical for maximally enhanced in vitro dissolution rates and
GI absorption to be reached. In particular, it is important not
only to consider the total amount of surfactant present in the
nanoparticles, but also its distribution within the particles, as
clearly demonstrated by the pronounced difference in PKI
release rate for hybrid nanoparticles for which surfactant was
dissolved together with polymer and drug in the organic
solvent prior to CO2 precipitation (bulk distribution), and
those for which surfactant was added after particle formation
(surface distribution).
CONCLUSIONS
Hybrid nanoparticles, formed by CO2-induced precipitation
of organic solutions containing a protein kinase inhibitor (PKI)
and amatrix-forming polymer, display dramatically improved
in vitro dissolution kinetics and GI absorption of PKIs. In such
hybrid materials, amorphous PKI is embedded within a poly-
mer matrix, preventing PKI crystallization and particle
growth. As demonstrated from increased dissolution rate,
the approach taken allows considerable flexibility in polymer
concentration, drug load, and nature of the matrix-forming
polymer. Surfactants added after hybrid nanoparticle gener-
ation is important for optimal PKI dissolution rate, presum-
ably a consequence of increased swelling and dissolution of the
polymermatrix, as well as facilitated PKI solubilization during
particle dissolution. With this, however, dramatically in-
creased dissolution rate was observed for both simulated gas-
tric fluid and simulated intestinal fluid. The increased dissolu-
tion rate observed in vitro translated into a strongly improved
bioavailability in vivo for male beagle dogs following oral
administration. Finally, the generality of the formulation ap-
proach taken was demonstrated for a range of PKIs.
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